Court Says Pfizer's Biosimilar of J&J's Remicade Doesn't Infringe Patent

Pfizer’s lower-priced version of Johnson & Johnson’s blockbuster autoimmune disease drug Remicade doesn’t infringe a patent, a federal court ruled, potentially clearing the way for the drug’s sale in October.

from WSJ.com: US Business http://ift.tt/2btIDCT
via IFTTT